Retinitis Pigmentosa
Conditions
Brief summary
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the efficacy and safety 0f RPE transplants to treat RP disease.
Detailed description
This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the efficacy and safety 0f RPE transplants to treat RP disease.
Interventions
BIOLOGICALRetinal pigment epitheliums transplantation
Subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums.
Sponsors
Qi Zhou
Beijing Tongren Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age above 18 and under 80 years of age, both gender, in good health. * Clinical diagnosis of retinitis pigmentosa, the results of eye electrophysiological examination accord with retinitis pigmentosa. * The BCVA of target eye will not be better than 20/400. * The BCVA of contralateral eye is not worse than 20/400. * Diopter is smaller than 8.00 D, axial 28 mm or less. * Voluntary as test subjects, signed informed consent, regular follow-up will be effected according to the specified time.
Exclusion criteria
* Subject with other additional retinal diseases, like diabetic or hypertensive retinopathy vascular diseases. * Target eye ever have had a eye surgery; * Subject with active serious diseases of the digestive system, liver kidney impairment (ALT/AST) \> 1.5 or any known liver disease, creatine \> 1.3 mg/dL) and/serious temic diseases, such as cardiovascular tem, respiratory tem, nervous tem, endocrine tem urogenital tem diseases, etc.), the history of malignancy; * Have been ready for pregnancy during test, are lactating women; * Ready to birth of men during the test; * Subject with any immunodeficiency; * Subject in the immunosuppressive therapy in the current; * Subject with the tacrolimus or other large ring lactone class drug allergies; * Participate in any clinical subjects in nearly six months; * Has a history of alcohol or illicit drug abuse; * Poor adherence to complete studies; * Researchers believe that there may be an increased risk subjects or interfere with the clinical trials of any situation (such as when a patient is prone to mental tension, depression, mental illness, cognitive dysfunction, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events and serious adverse events occurred within 1 year after transplantation | one year | The occurrence of adverse events (AE), severe adverse events (SAE), treatment-related adverse events (TEAE), and clinically significant vital signs during the study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of visual function | one year | The changes of BCVA and EDTRS were observed one year after surgery. |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORZhou Qi, Doctor
Institute of Zoology, Chinese Academy of Sciences
Outcome results
None listed